PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2035-2042

  Wan, Jing ^a   Li, Xiaomao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Co activator; Endometrial carcinoma; Glutamic acid and leucine rich protein 1 modulator of non genomic activity of estrogen receptor; Metastasis; Proline

Indexed keywords

CELL NUCLEUS RECEPTOR; GELATINASE A; GELATINASE B; MODULATOR OF NON GENOMIC ACTIVITY OF ESTROGEN RECEPTOR; PROLINE GLUTAMIC ACID LEUCINE RICH PROTEIN 1; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE SEQUENCE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CO-REPRESSOR PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84868090299     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2038     Document Type: Conference Paper

References (35)

1. Whitcomb BP: Gynecologic malignancies. Surg Clin North Am 88:301-317, vi, 2008. (Pubitemid 351434424)
2. Zhang H: Endocrine-related cancer. In: Encyclopedia of Cancer. Schwab M (ed). 2nd edition. Springer-Verlag, Heidelberg, pp435-439, 2008.
3. Shang Y: Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6:360-368, 2006.
4. Pietras RJ, Levin ER and Szego CM: Estrogen receptors and cell signaling. Science 310:51-53, 2005.
5. Shao W and Brown M: Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 6:39-52, 2004. (Pubitemid 38195559)
6. O'Lone R, Frith MC, Karlsson EK and Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol 18:1859-1875, 2004. (Pubitemid 39022608)
7. Bjornstrom L and Sjoberg M: Mechanisms of estrogen receptor signaling: convergence of genomic and non-genomic actions on target genes. Mol Endocrinol 19:833-842, 2005. (Pubitemid 40397050)
8. Song RX, Zhang Z and Santen RJ: Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab 16:347-353, 2005. (Pubitemid 41338739)
9. Losel R and Wehling M: Non-genomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46-56, 2004.
10. Mckenna NJ, Lanz RB and O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344, 1999. (Pubitemid 30649811)
11. Hall JM and Mcdonnell DP: Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 5:343-357, 2005. (Pubitemid 43060715)
12. Barnes CJ, Vadlamudi RK and Kumar R: Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 61:281-291, 2004. (Pubitemid 38223405)
13. Han SJ, Demayo FJ, Xu J, Tsai SY, Tsai MJ and O'Malley BW: Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. Mol Endocrinol 20:45-55, 2006. (Pubitemid 43011669)
14. O'Malley BW: Coregulators: from whence came these master genes'. Mol Endocrinol 21:1009-1013, 2007. (Pubitemid 46984754)
15. Sakaguchi H, Fujimto J and Sun WS: Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J Steroid Biochem Mol Biol 104:237-240, 2007. (Pubitemid 46891818)
16. Lanard DM, Lanz RB and O'Malhy BW: Nuclear receptor coregulators and human disease. Endocr Rev 28:575-587, 2007. (Pubitemid 47236337)
17. Gururaj AE, Singh RR and Rayala SK: MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci USA 103:6670-6675, 2006.
18. Webb P, Valentine C and Nguyen P: ER beta binds N-CoR in the presence of estrogens via an LXXLL-like motif in the N-CoR C-terminus. Nucl Recept 1:4, 2003.
19. Mishra SK, Balasenthil S and Ngnyen D: Cloning and functional characterization of PELP1/MNAR promoter. Gene 330:115-122, 2004. (Pubitemid 38490424)
20. Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schüle R, Brann DW, Tekmal RR and Vadlamudi RK: PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 11:438-444, 2010.
21. Cheskis B J, Greger J, Cooch N, et al: MNAR plays an important role in ERα activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 73:901-905, 2008.
22. Rajhans R and Vadlamudi RK: Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis 23:1-7, 2006. (Pubitemid 44576774)
23. Vadlamudi RK and Kumar R: Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 5:e004, 2007.
24. Nair SS, Guo Z, Mueller J M, et al: PELP1/MNAR enhances androgen receptor functions through LIM-only coactivator FHL2. Mol Endocrinol 21:613-624, 2007.
25. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR and Vadlamudi RK: Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res 67:5505-5512, 2007. (Pubitemid 46997292)
26. Habashy HO, Powe DG, Rakha EA, et al: The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 120:603-612, 2010.
27. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA and Kumar R: Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. Clin Endocrinol Metab 89:6130-6138, 2004. (Pubitemid 39628425)
28. Dimple C, Nair SS, Rajhans R, et al: Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 68:4902-4909, 2008.
29. O'Malley BW and Kumar R: Nuclear receptor coregulators in cancer biology. Cancer Res 69:8217-8222, 2009.
30. Chakravarty D, Tekmal RR and Vadlamudi RK: PELP1: a novel therapeutic target for hormonal cancers. IUBMB Life 62:163-169, 2010.
31. Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L and Vadlamudi RK: Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res 10:25-33, 2012.
32. Balasenthil S and Vadlamudi RK: Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 278:22119-22127, 2003. (Pubitemid 36792622)
33. Nair BC, Nair SS, Chakravarty D, et al: Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res 70:7166-7175, 2010.
34. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK and Vadlamudi RK: Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 17:2250-2259, 2011.
35. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174, 2002. (Pubitemid 37328786)